Patients from 22+ countriesPlan your visit →
lutetium-therapy
Caregiver Treatment Decisions · 13 Sept 2026

Lu-177 PSMA Therapy for Your Father After Chemo

If your father has metastatic prostate cancer and chemotherapy has stopped working, Lu-177 PSMA therapy may be the next step worth understanding. This guide covers eligibility, what the evidence shows, and exactly what to bring to his next oncology appointment.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 13 Sept 2026
Lu-177 PSMA Therapy for Your Father After Chemo

Lu-177 PSMA Therapy for Your Father After Chemo

This article explains Lu-177 PSMA therapy - a radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). It helps adult children understand what comes after chemotherapy stops working. This covers the treatment path for men whose prostate cancer has spread and no longer responds to standard hormone therapy or taxane-based chemotherapy.

Being the adult child in this situation is difficult. You're absorbing medical information quickly, asking the right questions, and helping someone you love make decisions about his body - while managing your own fear. This guide gives you an understanding of what Lu-177 PSMA therapy is, who qualifies, what the research shows, and what to do next.

What Does It Mean When Chemotherapy Stops Working in Prostate Cancer?

Metastatic castration-resistant prostate cancer means the cancer has spread - most often to the bones and lymph nodes - and is growing despite testosterone-lowering treatment. Oncologists usually start with hormone-targeting drugs called androgen receptor pathway inhibitors, or ARPIs. Examples include enzalutamide and abiraterone. When those stop controlling the disease, taxane-based chemotherapy drugs such as docetaxel or cabazitaxel are typically tried next.

When chemotherapy also stops controlling the cancer, a man has progressed past two major lines of systemic therapy. That doesn't mean all options are gone. It means standard oncology options have limits. Radioligand therapy - specifically Lu-177 PSMA therapy - is a targeted approach that becomes relevant at exactly this point in many men's treatment histories.

How Does Lu-177 PSMA Therapy Work?

Prostate-specific membrane antigen, or PSMA, is a protein on the outer surface of most prostate cancer cells. The higher the PSMA expression, the easier it is to target those cells.

Lu-177 PSMA therapy works by attaching a radioactive molecule - lutetium-177 - to a small chemical that finds and binds to the PSMA protein. Once infused into the bloodstream, this molecule travels through the body and locks onto PSMA-expressing cancer cells. It then delivers a focused dose of radiation to those cells from the inside, at very short range. Healthy cells nearby receive far less radiation than they would from external-beam radiotherapy or whole-body chemotherapy.

The concept behind this approach is called theranostics - using the same targeting molecule both to image the cancer on a PET scan and to treat it by swapping the imaging isotope for a therapeutic one. The same PSMA receptor that lights up on the diagnostic scan is the one the therapy uses to find and attack cancer cells. As the Prostate Cancer Foundation explains in its overview of PSMA radioligand therapy, this precision is what distinguishes the approach from chemotherapy, which circulates throughout the whole body.

For a more detailed explanation of why this approach is particularly relevant after chemotherapy, see our article on why Lu-177 PSMA works after chemotherapy fails.

Is Your Father Eligible? Four Things That Determine It

Understanding eligibility before the appointment is one of the most useful things you can do as a caregiver. Here are the four main criteria.

1. Prior Treatment History

For the post-chemotherapy indication, the US Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) in March 2022 for adults with PSMA-positive mCRPC who had received at least one ARPI and one or two taxane-based chemotherapy regimens. If your father has had both of these - a hormone-targeting drug like enzalutamide or abiraterone, and a chemotherapy drug like docetaxel or cabazitaxel - he meets the prior-treatment threshold for this indication. The FDA has since expanded the approval in some settings, so ask his oncologist which approval pathway applies to his specific case.

2. PSMA Expression on Imaging

The therapy only works if the cancer cells express enough PSMA to serve as a target. This is confirmed through a PSMA-PET scan - a nuclear medicine imaging test in which a radioactive tracer binds to PSMA-expressing tissue and makes it visible on a scan. In the VISION trial - the large global phase 3 study that led to the FDA approval - the standard was that at least one tumor lesion needed to show uptake greater than that of normal liver tissue on the scan. If your father has not had this scan, it is the first practical step toward knowing whether he is eligible. Our page on what your PSMA-PET results mean for Lu-177 eligibility walks through the key findings to look for in the report.

3. Day-to-Day Functioning

Oncologists use a scale called the ECOG performance status to assess how well a person is functioning day to day. In the VISION trial, eligible patients typically had an ECOG score of 0 or 1 - meaning they were fully active or had only minor restrictions on daily activity. If your father is spending more than half of his waking hours in bed, the treatment team will assess carefully whether treatment is appropriate and safe.

4. Blood Counts and Kidney Function

Lu-177 PSMA therapy affects the bone marrow and the kidneys over the course of treatment. Before starting, his team will check his full blood count and his kidney function through a measurement called the glomerular filtration rate, or GFR. If either of these is already severely impaired, the treatment team will weigh the risks and benefits carefully before proceeding.

What Does the Evidence Show?

The pivotal VISION trial was a large, global phase 3 study of lutetium Lu-177 vipivotide tetraxetan added to standard of care in men with PSMA-positive mCRPC who had already received ARPI therapy and taxane-based chemotherapy. The National Cancer Institute summarised the VISION findings: the treatment improved overall survival and radiographic progression-free survival compared to standard of care alone. Median overall survival was 15.3 months in the lutetium Lu-177 group versus 11.3 months in the control group. The hazard ratio for overall survival was 0.62, and the hazard ratio for radiographic progression-free survival was 0.40 - both statistically significant findings.

These numbers describe averages across a wide and varied group of patients. Some men see stronger responses; some do not respond at all. Research also shows that a decline in PSA levels during treatment is associated with better outcomes. Monitoring PSA trends across cycles is part of how the treatment team tracks how well the therapy is working. Our article on Lu-177 PSMA therapy and realistic response rates gives a grounded picture of what to expect before the consultation.

What Happens During Treatment

If your father qualifies and chooses this path, treatment is given as an intravenous infusion in a specialist nuclear medicine unit. The standard regimen is one infusion of 7.4 gigabecquerels (GBq) every six weeks, for up to six cycles. Each infusion session typically takes about two hours.

The most commonly reported side effects, according to clinical data reviewed by Mayo Clinic, include fatigue, dry mouth, nausea, reduced appetite, and mild anemia. Dry mouth occurs because the salivary glands also express PSMA and absorb some of the treatment. Most of these effects are mild to moderate and you can manage them between cycles. In a smaller proportion of patients, blood counts drop more significantly - a condition called myelosuppression - and this is monitored through regular blood tests between infusions.

After each infusion, your father will carry a low level of radioactivity for a few days. His care team will give specific written guidance on precautions at home: for example, maintaining some distance from young children and pregnant women, and handling bathroom surfaces and linens carefully in the first few days after treatment. These precautions end before the next cycle and are entirely temporary. For the full picture of what caregiving looks like between cycles - including what to watch for and when to call the team - see our Lu-177 PSMA caregiver guide for mCRPC families.

Questions to Bring to the Appointment

Going in prepared changes the quality of the conversation. Here are specific questions worth raising at your father's next appointment.

  • Has my father had a PSMA-PET scan? If not, which one would you recommend - and where can it be arranged?
  • Has he received at least one ARPI and at least one taxane-based chemotherapy regimen?
  • What are his current kidney function and blood count numbers, and do they meet the threshold for this treatment?
  • Does this center offer Lu-177 PSMA therapy, or would you refer us to a specialist nuclear medicine unit?
  • If he is not currently eligible, what would need to change for him to become a candidate?
  • Are there clinical trials he might qualify for that use a radioligand or PSMA-targeted approach?

If his current oncologist hasn't mentioned radioligand therapy as an option, there are a few possible reasons: the center may not offer it, local access may be limited, or his case may need specialist review. That's a reasonable moment to seek an independent assessment. You can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for your father - and what alternatives exist if it is not.

When Access Is the Barrier, Not Eligibility

In many countries - particularly across the Gulf, Sub-Saharan Africa, South Asia, and parts of Southeast Asia - Lu-177 PSMA therapy is unavailable locally or has waiting times of many months. If your father meets the eligibility criteria but cannot access treatment where he lives, you might travel to a country with accredited nuclear medicine centers, such as India.

India has specialist centers offering lutetium Lu-177 vipivotide tetraxetan at costs significantly lower than in the US or UK. A full course of up to six cycles can often fit within a single extended stay or two shorter visits. Our guide on Lu-177 PSMA treatment cost in India versus the US and the UK breaks down what to expect per cycle and how to plan the logistics for families arriving from abroad.

Coordinating a parent's cancer care across borders is one of the more demanding things a family can take on. Starting the conversation with his care team early helps you arrange imaging, confirm eligibility, and - if needed - plan access to a specialist center.

When to Talk to Your Father's Doctor

Raise Lu-177 PSMA therapy with his oncologist if chemotherapy is no longer working, if he has not yet had a PSMA-PET scan, or if radioligand therapy has not come up as a next step. Bringing it into the conversation early gives more time to arrange imaging, confirm eligibility, and - if needed - plan access to a specialist center. These steps take time, and starting sooner helps.

If you want to understand what ongoing monitoring looks like after a full treatment course - including how PSA trends are followed and what follow-up scans involve - our article on what to expect three to six months after Lu-177 PSMA therapy is a useful read at this stage of planning.

You can also contact the Lutetium Therapy team to request an eligibility review. Send your father's PSMA-PET scan results, his treatment history, and his most recent blood work. If Lu-177 PSMA therapy is not the right fit for his situation, the team can help identify what alternatives may be worth exploring with his oncologist.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does my father need to have failed both hormone therapy AND chemotherapy to qualify for Lu-177 PSMA therapy?

For the original post-chemotherapy FDA indication, he would need to have received at least one androgen receptor pathway inhibitor - a hormone-targeting drug like enzalutamide or abiraterone - and at least one taxane-based chemotherapy regimen such as docetaxel or cabazitaxel. However, the FDA has since expanded the approval in some settings, and eligibility criteria vary by country and treating center. His oncologist can confirm which indication applies to his case and whether he meets the threshold.

What does PSMA-positive mean, and how do we find out if my father's cancer qualifies?

PSMA stands for prostate-specific membrane antigen - a protein on the surface of most prostate cancer cells. PSMA-positive means the cancer expresses this protein at a level high enough to be imaged and targeted by the therapy. The way to confirm this is through a PSMA-PET scan: a nuclear medicine imaging test in which a small radioactive tracer binds to PSMA-expressing tissue and lights it up on the scan. Ask his oncologist for a referral to a nuclear medicine department if he has not had one. The scan also shows where in the body the cancer has spread, which helps the treatment team plan.

How long does a full course of Lu-177 PSMA therapy take from first infusion to last?

The standard course is up to six infusions, each given six weeks apart. If he completes all six cycles, the full course spans about 30 weeks - roughly seven months. Some patients receive fewer cycles based on how they respond or how side effects are managed. Blood counts and kidney function are tested before each cycle to assess whether it is safe and appropriate to continue.

What radiation safety precautions does our family need to take after each infusion?

After each infusion, your father will carry a low level of radioactivity for a few days - typically three to five days, though the care team will give exact written guidance specific to the facility and country. Common precautions include maintaining some distance from young children and pregnant women, using a separate bathroom if possible, and handling linens and body fluids carefully in the first few days. These precautions are temporary and lift well before the next cycle. Always follow the written instructions from his nuclear medicine team.

If Lu-177 PSMA therapy is not available in our country, is traveling to India realistic?

For families from the Gulf, Africa, and South or Southeast Asia, traveling to India for Lu-177 PSMA therapy is an increasingly common route. India has accredited nuclear medicine centers offering the treatment at costs significantly lower than in the US or UK. Logistics - including medical visa, accommodation near the treatment center, and whether to stay in India between cycles or return home - can be planned in advance. A teleconsultation before booking travel can confirm eligibility and help you time the cycles around travel windows.

What happens if my father turns out not to be eligible for Lu-177 PSMA therapy?

If the PSMA-PET scan shows low or no PSMA expression, or if his blood counts or kidney function do not meet the required thresholds, his oncologist will discuss other options. These may include clinical trials, other targeted therapies such as PARP inhibitors if he carries certain gene mutations, or revised sequencing of available treatments. A second opinion from a theranostics or nuclear medicine specialist is always reasonable before accepting that a particular treatment path is closed.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA After Chemo: Adult Children's Guide | lutetium-therapy